Evidence map›Paper›PMID 19150386›Full record

ArticleMolecular and cellular endocrinology2009

Cytoplasmic localization of the androgen receptor is independent of calreticulin.

Minh M Nguyen, Zehra Dincer, James R Wade, Mahesh Alur, Marek Michalak, Donald B Defranco, Zhou Wang

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular endocrinology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Calreticulin as a marker and therapeutic target for cancer.Clinical and experimental medicine · 2023
    Review
  3. Review
  4. Article
  5. The classical and updated models of androgen receptor nucleocytoplasmic trafficking.American journal of clinical and experimental urology · 2021
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Characterization of karyopherins in androgen receptor intracellular trafficking in the yeast model.International journal of clinical and experimental pathology · 2014
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Minh M NguyenDepartment of Urology, University of Pittsburgh Cancer Institute, School of Medicine, Pittsburgh, PA 15232, United States.
Zehra Dincer
James R Wade
Mahesh Alur
Marek Michalak
Donald B Defranco
Zhou Wang
UPMC Hillman Cancer Center · US

Funding

SUPPRESSIVE ROLE OF ANDROGEN RESPONSE GENE CALRETICULIN IN PROSTATE CANCERP50CA090386 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CRAWFORD, SUSAN · 2001 to 2013
$25.1M
TRAINING PROGRAM IN ONCOGENESIS &DEVELOPMENT BIOLOGYT32CA080621 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI EKLUND, ELIZABETH ANN · 2001 to 2018
$4.1M
Role of U19/Eaf2 in androgen-dependent prostate homeostasisR37DK051193 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, ZHOU · 2006 to 2013
$2.5M
AR intracellular trafficking in prostate cancerR01CA108675 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, ZHOU · 2005 to 2009
$1.3M
NCI NIH HHS 1 P50 CA90386NCI NIH HHS P50 CA090386NCI NIH HHS R01 CA108675NCI NIH HHS R01 CA108675-01NCI NIH HHS T32 CA080621NIDDK NIH HHS R37 DK051193NIDDK NIH HHS R37 DK51193
6 · The paper itself

Abstract

Identification and characterization of factors regulating intracellular localization of the androgen receptor (AR) are fundamentally important because nucleocytoplasmic trafficking of AR is a critical step in AR regulation by androgen manipulation. Normally, AR is localized to the cytoplasm in the absence of androgen. Upon ligand binding, AR translocates to the nucleus, where it can modulate transcription of AR-responsive genes. The withdrawal of androgen results in the export of unliganded AR from the nucleus to the cytoplasm, where it is transcriptionally inactive. Calreticulin has been implicated as a possible nuclear export factor for AR because the two proteins form a complex. In this study, we assessed whether the cytoplasmic localization of AR requires binding to calreticulin. To test this we substituted the calreticulin binding sequence (CBS) KVFFKR (residues 579-584) with the amino acids RLAARK in AR and monitored the cellular localization of a GFP-AR fusion protein in the absence of androgen. We also determined if knockdown or knockout of calreticulin expression affected the cytoplasmic localization of the AR. We found that a mutated CBS did not affect the localization of AR and that in the absence of androgen, AR is localized to the cytoplasm regardless of its ability to interact with calreticulin. Also, a reduction in the levels or loss of calreticulin did not affect the localization of AR. These data argue that calreticulin is not required for the cytoplasmic localization of AR.

Indexed as

Binding SitesCalreticulinCell Line, TumorCytoplasmGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMaleNuclear PoreNuclear ProteinsProstatic NeoplasmsReceptors, AndrogenCalreticulinNuclear ProteinsReceptors, Androgen

Identifiers

PMID19150386
PMCPMC2806808
OpenAlexW1993170781

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.